Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
SAB Biotherapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/21/2023 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
07/31/2023 8-K Quarterly results
07/03/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/12/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation "
04/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Press Release of the Company"
04/19/2023 8-K Quarterly results
04/14/2023 8-K Quarterly results
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors SIOUX FALLS, S.D., April 4, 2023 -- SAB Biotherapeutics , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the appointment of Erick Lucera, CFA, a veteran of the biotechnology and medical device industry, with over thirty years of financial, operational and investment experience, to SAB’s Board of Directors, effective April 4, 2023. Most recently, Mr. Lucera served as chief financial officer for AVEO Oncology, a commercial stage oncology-focused biopharmaceutical company, from January 202..."
03/31/2023 8-K Quarterly results
Docs: "Press Release of the Company"
03/24/2023 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregister...
02/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Presentation"
01/27/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/09/2023 8-K Quarterly results
01/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
11/21/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ADVANCING A POWERFUL NEW CLASS"
11/07/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "2022 SAB BIOTHERAPEUTICS, INC. TARGET FDA: CENTER FOR BIOLOGICS EVALUATION",
"2022 SAB BIOTHERAPEUTICS, INC. 8 SAB-185"
10/13/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "THIS FOURTH AMENDMENT TO AMENDED AND RESTATED LEASE AGREEMENT is made as of October 11, 2022, by and between Sanford Health, a South Dakota non-profit corporation , and SAB Biotherapeutics, Inc., a Delaware corporation . RECITALS A. Landlord and Tenant are parties to that certain Amended and Restated Lease Agreement dated as of September 1, 2019 . B. Landlord and Tenant have agreed to enter into this Amendment for the purpose of reducing the amount of space Tennant is renting from Landlord and providing a rent abatement in exchange for a promissory note and other considerations. C. Capitalized terms used herein but not otherwise defined herein shall have the meanings ascribed to such terms in the Lease. AGREEMENTS NOW, THEREFORE, in consideration of the mutual covenants set forth in this A..."
10/07/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
09/30/2022 8-K Quarterly results
09/28/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "D E F G H I J K L M N O",
"2022 SAB BIOTHERAPEUTICS, INC. EXHIBIT"
09/23/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ADVANCING A POWERFUL NEW CLASS"
07/11/2022 8-K Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibit...
Docs: "MBA, CMA CHIEF FINANCIAL OFFICER",
"SAB Biotherapeutics Announces Election of Rear Admiral Scott Giberson, RPh, MPH, D.Sc., to Board of Directors SIOUX FALLS, S.D., July 11, 2022 -- SAB Biotherapeutics , , a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Rear Admiral , retired, Scott Giberson, a former Assistant U.S. Surgeon General and two-star admiral with the U.S. Public Health Service to SAB’s Board of Directors, effective July 7, 2022. RADM Giberson retired after a decorated career and 27 years of service. In 2018, the Military Officers Association of America selected him as one of the “Top 100 Veterans in the Last 100 Years you Ne..."
07/05/2022 8-K Quarterly results
06/07/2022 8-K Quarterly results
06/06/2022 8-K Quarterly results
01/10/2022 8-K Regulation FD Disclosure  Interactive Data
01/06/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/22/2021 8-K/A Financial Statements and Exhibits  Interactive Data
Docs: "SAB BIOTHERAPEUTICS MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS",
"UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION"
11/22/2021 8-K Quarterly results
Docs: "SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update"
11/19/2021 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement , dated as of November 17, 2021 and effective as of October 25, 2021 , is entered into by and between SAB BIOTHERAPEUTICS, INC., a Delaware corporation , and Samuel J. Reich, an individual residing at 3437 Prairie Ave, Miami Beach, FL 33141 . 1. POSITION AND RESPONSIBILITIES 1.1. Position. During the Term of this Agreement, Executive shall be employed by the Company to render services to the Company in the position of Executive Chairman, Board of Directors . In this capacity, Executive shall perform such duties and carry out such responsibilities as the Board may lawfully and reasonably request, including, but not limited to, assisting in the development of corporate strategy for the Company’ s near and long-term growth, finance acti..."
10/28/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ...
Docs: "BY LAWS OF SAB BIOTHERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.1 Registered Office. The registered office of the Corporation within the State of Delaware shall be located at either the principal place of business of the Corporation in the State of Delaware or the office of the corporation or individual acting as the Corporation’ s registered agent in Delaware.",
"AMENDED AND RESTATED STOCKHOLDER AND REGISTRATION RIGHTS AGREEMENT",
"RECITALS",
"LIST OF SUBSIDIARIES SAB Sciences, Inc., a Delaware Corporation Diversity Therapeutics, Inc., a Delaware Corporation SAB LLC, a South Dakota LLC SAB Capra LLC, a South Dakota LLC Aurochs LLC, a South Dakota LLC"
10/21/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy